Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 663

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 6
Chunk 663
---
 SHARES OF COMMON STOCK OUTSTANDING - BASIC AND DILUTED 
     165,061,967  
     97,511,557 

The accompanying notes are an integral part of these
consolidated financial statements.

F-5

LUNAI BIOWORKS INC. FKA: RENOVARO INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

    For the Years Ended

    June 30,

    2025 
    2024

    Net Loss 
    $(178,007,489) 
    $(88,425,828)
  
    Other Comprehensive Income (Loss) 

    Foreign currency translation, net of taxes 
     109,985,688  
     (140,964)

    Comprehensive Loss 
    $(167,021,801) 
    $(88,566,792)

The accompanying notes are an integral part of these
consolidated financial statements.

F-6

LUNAI BIOWORKS INC. FKA: RENOVARO INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY (DEFICIT)

For the Years Ended June 30, 2025 and June 30, 2024

    # of Preferred Shares 
    Preferred Shares Amount 
    # of Common Shares 
    Common Stock Amount 
    Additional Paid-In Capital 
    Accumulated Deficit 
    Accumulated Other Comprehensive Income (Loss) 
    Total
  
    Balance June 30, 2023 
     —  
     —  
     63,698,144  
     6,371  
     290,554,875  
     (244,029,253) 
     (29,882) 
     46,502,111 
  
    Issuance of preferred stock and warrants in private placement 
     280,505  
     28  
     —  
     —  
     1,999,972  
     —  
     —  
     2,000,000 
  
    Issuance of preferred stock and warrants for conversion of Note Payable 
     280,505  
     28  
     —  
     —  
     1,999,973  
     —  
     —